Reduce Sedentary Behavior During Cancer Treatment - the RedSedCan Study
RedSedCan
1 other identifier
interventional
172
1 country
2
Brief Summary
Summary Reducing sedentary behavior during treatment is important to reduce the risk of future health problems in individuals undergoing cancer treatment. Therefore, the goal of this project is with a multicenter randomised controlled design investigate whether a digital support intervention during ongoing neo- or adjuvant cancer treatment for breast, prostate or colon cancer is effective in reducing sedentary lifestyle and improving well-being in the short and long term.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable breast-cancer
Started Mar 2025
Longer than P75 for not_applicable breast-cancer
2 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
November 19, 2024
CompletedFirst Posted
Study publicly available on registry
December 5, 2024
CompletedStudy Start
First participant enrolled
March 1, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 31, 2029
ExpectedStudy Completion
Last participant's last visit for all outcomes
December 31, 2030
January 30, 2026
January 1, 2026
4.8 years
November 19, 2024
January 28, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Sedentary behavior time
The Axivity accelerometer is used for measuring the primary outcome of sedentary time, i.e. mean time spent in sedentary behavior/day.
At baseline, 3-months, 6 months, 12 months and 24 months. Axivity is worn for 7 consecutive days at each measurement point.
Secondary Outcomes (10)
Sedentary behavior bouts
At baseline, 3-months, 6 months, 12 months and 24 months. Axivity is worn for 7 consecutive days at each measurement point.
Physical activity
At baseline, 3-months, 6 months, 12 months and 24 months. Axivity is worn for 7 consecutive days at each measurement point.
Health-related quality of life
At baseline, 3-months, 6 months, 12 months and 24 months.
Health-related quality of life
At baseline, 3-months, 6 months, 12 months and 24 months.
Cancer related fatigue
At baseline, 3-months, 6 months, 12 months and 24 months.
- +5 more secondary outcomes
Other Outcomes (8)
Demographic variables
Baseline
Diagnoses
At baseline
Cancer treatment
At baseline, 3-months, 6 months, 12 months and 24 months.
- +5 more other outcomes
Study Arms (2)
Intervention
EXPERIMENTALParticipants receive a digital support intervention
Control
NO INTERVENTIONControl condition. Individuals receive the care as usual provided by the healthcare only.
Interventions
The program consists of commercially available technologies, e.g. applications including behavour change techniques for reducing sedentary behavior (SB) (i.e. self-monitorization of physical activity, reminders for breaking SB/doing physical activity, and providing feedback on physical activity/breaks from SB) and a webpage containing information and tips (provided in short videos and text) regarding how to reduce SB. The participants will be receive help with setting goals for reducing time spent in sedentary/being active and help with planning for what activities to do to replace time in sedentary. Participants will then have access to the webpage and download the application to their smartphones. Follow-up meetings with the physiotherapist (digital or physical) will be conducted after 2, 8 and 12 weeks after start of intervention.
Eligibility Criteria
You may qualify if:
- Individuals diagnosed with breast, prostate, or colorectal cancer planned for or resently started neo- or adjuvant treatment (e.g. chemotherapy, radiotherapy, endocrine treatment) at the hospitals in Uppsala and Västerås, Sweden.
You may not qualify if:
- Individuals diagnosed with dementia.
- Individuals diagnosed with severe psychiatric disease.
- Individuals with severe loss of vision, or communicative ability.
- Individuals who cannot walk independently indoors with or without a walking aid.
- Individuals completed treatment for other cancer diseases less than 12 months ago or not recovered from previous cancer treatment.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Region Västmanlandcollaborator
- Uppsala Universitycollaborator
- Centrallasarettet Västeråscollaborator
- Uppsala University Hospitalcollaborator
- Mälardalen Universitylead
- Uppsala County Council, Swedencollaborator
Study Sites (2)
Akademiska sjukhuset
Uppsala, Sweden
Västmanlands sjukhus
Västerås, Sweden
Related Links
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Petra von Heideken Wågert, Professor
Mälardalen University
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- SUPPORTIVE CARE
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
November 19, 2024
First Posted
December 5, 2024
Study Start
March 1, 2025
Primary Completion (Estimated)
December 31, 2029
Study Completion (Estimated)
December 31, 2030
Last Updated
January 30, 2026
Record last verified: 2026-01
Data Sharing
- IPD Sharing
- Will not share
Individual medical information may not be shared with other researchers if the research questions are not within the scope of the current approved Swedish Ethical Review Board application (and any amendments) for this research. Only pseudonymous information may be shared after approval has been provided from the Swedish Ethical Review Board.